October 17, 2026 01:42 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
'How dare Elon Musk?' Owaisi defends Modi after billionaire's 'real boss' jibe at Ambani | 'B****y S***': IAS officer's abuse of female colleague during virtual J&K meeting sparks row | Aamir Khan’s nephew Imran Khan asked to leave India by Oct 28 after joining anti-CEC protest | ‘Their crime? Demanding justice’: Rahul Gandhi slams 4 AM detention of Ankita Bhandari’s parents | ‘Bangladesh showed us the way’: Neha Bora’s remarks spark BJP attack on Rahul Gandhi | Chingrighata flyover skid scare: Bikes fall, anti-skid blocks installed overnight as Bengal Minister Agnimitra Paul faces criticism | Meerut blue drum murder case: Muskaan, her lover get death sentence | 'Rise up, young patriots!': American singer Mary Millben alleges CJP gets US funding, urges peaceful protests | 'Won't go unchallenged': Muhammad Yunus heckling in New York triggers legal action warning | flydubai cockpit attack probe widens: Two Maldivian pilots detained in UAE over links to Omani co-pilot
AstraZeneca
Pixabay

AstraZeneca's COVID-19 vaccine trial to resume in US

| @indiablooms | Oct 24, 2020, at 03:28 pm

Washington/Xinhua: Multinational pharmaceutical company AstraZeneca said on Friday it will resume the trial of its experimental COVID-19 vaccine in the United States, which has been paused since September.

The company said the U.S. Food and Drug Administration (FDA) authorized the restart of the trial in the United States on Friday, following the resumption of trials in other countries in recent weeks.

The FDA reviewed all safety data from trials globally and concluded it was safe to resume the trial, said the company in a statement.

As part of the standard review process for trial safety events, a voluntary pause to vaccination across all global trials was triggered on Sept. 6 to allow the examination of safety data by independent monitoring committees, according to the company.

The recommendations from these reviews have been supported by international regulators, who also confirmed that the trials were safe to resume, said the statement.

AstraZeneca said results from the late-stage trials are expected later this year.  

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.